论文部分内容阅读
目的:探讨对新诊断2型糖尿病患者给予沙格列汀联合口服降糖方案的有效性及安全性。方法收集50例新诊断的2型糖尿病随机分为观察组和对照组,对照组使用二甲双胍常规治疗,观察组加用沙格列汀,随后24周、观察后FPG,2hPG和HbA1C等有效性指标及BMI低血糖发生情况。结果观察后FPG和HbA1C相对于对照组显著下降,(P<0.05)观察组HbA1C达标率为85%,显著高于对照组的72%(P<0.05),两组治疗后BMI及低血糖发生率差异无统计学意义。结论:沙格列汀与二甲双胍联合治疗T2DM降糖效果更好,对体重无影响不增加低血糖风险。
Objective: To investigate the efficacy and safety of oral salbutamol combined with oral hypoglycemic regimen in newly diagnosed type 2 diabetic patients. Methods Fifty newly diagnosed type 2 diabetes mellitus patients were randomly divided into observation group and control group. The control group was treated with metformin, and the observation group plus saxagliptin, then 24 weeks. The effective indexes of FPG, 2hPG and HbA1C were observed. And BMI hypoglycemia occurred. Results After the observation, FPG and HbA1C were significantly decreased compared with the control group (P <0.05). The HbA1C compliance rate in the observation group was 85%, which was significantly higher than that in the control group (P <0.05). The BMI and hypoglycemia No significant difference in rates. Conclusions: The combination of saxagliptin and metformin is superior to hypoglycemic T2DM in reducing the risk of hypoglycemia.